After the recent report of the positive PhIIB data, ClinicalTrials is resporting Merck has filed to move forward and starting the 2nd Phase 3 on BACE. Don't need to tell any longs that success with BACE could be a massive win for $LGND.
Good find. There are recent basic research results that support the idea that BACE inhibition can prevent Alzheimer's. Consistent with this, MRK is aggressively pushing MK-8931 program. Agree that if MK-8931 successful, it will be substantial, probably bigger than Lipitor as I posted previously.